Companies · NVO
Novo Nordisk
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Nov 5, 2026
CSO Disposes DKK 3.4M Share Position; Insider Selling amid Healthcare Valuation Cycle
Novo Nordisk filed a routine Form 6-K disclosing an insider sale by Martin Holst Lange, Executive Vice President R&D and Chief Scientific Officer, of 12,000 shares at DKK 285 per share on 4 November 2026. This transaction—totaling DKK 3.42 million—is a routine Article 19 market-abuse notification required by EU regulation and carries no strategic implication regarding company operations or clinical pipelines. The sale reflects standard portfolio management by a senior executive with equity exposure.
Tone: neutralRevenue
DKK 309.1B
NVO 20-F · FY 2025 · DKK
Employees
69,500
Revenue FY2024
DKK 290.4B
Founded
1923
Profile
NVO 20-F Item 4.B · Feb 4, 2026Novo Nordisk is a global pharmaceutical company headquartered in Denmark, specializing in obesity and diabetes care as well as rare diseases. The company manufactures and markets GLP-1 receptor agonists, modern and human insulins, blood-clotting factors, and growth hormone therapies. It operates in approximately 170 countries with more than 69,500 employees.
Read filing description ↓ Collapse description ↑
Novo Nordisk is a global healthcare company and a world leader in Obesity and Diabetes care. The Company manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. Headquartered in Denmark, Novo Nordisk employs more than 69,500 employees in around 80 countries, and markets its products in approximately 170 countries. The Company has a broad product portfolio across Obesity and Diabetes care and Rare disease, including a portfolio of glucagon-like-peptide-1 (GLP-1) receptor agonists for the treatment of obesity and diabetes, and modern and human insulins for the treatment of diabetes. During 2025, there has been continued growth across all therapy areas and in many of the geographic areas in which Novo Nordisk operates. However, due to increased competition in both US and ex-US markets, Novo Nordisk has lost volume market share in the GLP-1 market places for both obesity and diabetes. The Company markets three drugs - Saxenda® and Wegovy®, which is offered in injectable formats and Wegovy® Pill that has recently launched in the first quarter of 2026 - for the treatment of obesity. Novo Nordisk also has a Rare disease portfolio consisting mainly of growth hormone and haemophilia products. On 10 September 2025, Novo Nordisk initiated a company-wide transformation to simplify its organisation, improve the speed of decision-making, and reallocate resources towards the company's growth opportunities in obesity and diabetes, resulting in approximately 9,000 employees being let go globally.
Primary products
- Ozempic®
- Wegovy®
- Rybelsus®
- Saxenda®
- Victoza®
- Awiqli®
Business segments
End markets
Geographies
Named competitors
“In the global diabetes market, Novo Nordisk and Eli Lilly are the most significant companies measured by market share.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Reported in DKK. Full consolidated income statement financials are incorporated by reference from the Annual Report 2025 and not reproduced in the extracted filing sections; total revenue figures are not determinable from the provided text.
The rest of NVO is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.